Evidence map›Paper›PMID 37953992›Full record

ArticleThe Lancet regional health. Europe2023

Elevated symptoms of depression and anxiety among family members and friends of critically ill COVID-19 patients - an observational study of five cohorts across four countries.

Anikó Lovik, Juan González-Hijón, Asle Hoffart, Chloe Fawns-Ritchie, Ingibjörg Magnúsdóttir, Li Lu, Anna Bára Unnarsdóttir, Anna K Kähler, Archie Campbell, Arna Hauksdóttir and 17 more

Open access · goldAbstract read
In one paragraph

Article in The Lancet regional health. Europe, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
  6. Frontiers in psychiatry · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 10 institutions in 7 countries.

Anikó LovikUnit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Juan González-HijónUnit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Asle HoffartDepartment of Psychology, University of Oslo, Oslo, Norway.
Chloe Fawns-RitchieCentre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, Scotland.
Ingibjörg MagnúsdóttirCentre of Public Health Sciences, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
Li LuHealth Management and Policy Institute, School of Public Policy and Administration, Xi'an Jiaotong University, Xi'an, China.
Anna Bára UnnarsdóttirCentre of Public Health Sciences, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
Anna K KählerDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden.
Archie CampbellCentre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, Scotland.
Arna HauksdóttirCentre of Public Health Sciences, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
Charilaos ChourpiliadisUnit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Daniel L McCartneyCentre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, Scotland.
Edda Björk ThordardóttirCentre of Public Health Sciences, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
Emily E JoyceUnit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Emma M FransDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden.
Jóhanna JakobsdóttirCentre of Public Health Sciences, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
Lill TrogstadDivision of Infection Control, Norwegian Institute of Public Health, Oslo, Norway.
Ole A AndreassenNORMENT Centre, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Per MagnusCentre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway.
Sverre Urnes JohnsonDepartment of Psychology, University of Oslo, Oslo, Norway.
Patrick F SullivanDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden.
Thor AspelundCentre of Public Health Sciences, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
David J PorteousCentre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, Scotland.
Helga AskDepartment of Psychology, University of Oslo, Oslo, Norway.
Omid V EbrahimiDepartment of Psychology, University of Oslo, Oslo, Norway.
Unnur Anna ValdimarsdóttirUnit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Fang FangUnit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Karolinska Institutet · SEUniversity of Iceland · ISNorwegian Institute of Public Health · NOEdinburgh Cancer Research · GBUniversity of Oslo · NOHarvard University · USLeiden University · NLOslo University Hospital · NOUniversity of Dundee · GBUniversity of North Carolina at Chapel Hill · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Little is known regarding the mental health impact of having a significant person (family member and/or close friend) with COVID-19 of different severity. Methods: The study included five prospective cohorts from four countries (Iceland, Norway, Sweden, and the UK) with self-reported data on COVID-19 and symptoms of depression and anxiety during March 2020-March 2022. We calculated prevalence ratios (PR) of depression and anxiety in relation to having a significant person with COVID-19 and performed a longitudinal analysis in the Swedish cohort to describe temporal patterns. Findings: 162,237 and 168,783 individuals were included in the analysis of depression and anxiety, respectively, of whom 24,718 and 27,003 reported a significant person with COVID-19. Overall, the PR was 1.07 (95% CI: 1.05-1.10) for depression and 1.08 (95% CI: 1.03-1.13) for anxiety in relation to having a significant person with COVID-19. The respective PRs for depression and anxiety were 1.15 (95% CI: 1.08-1.23) and 1.24 (95% CI: 1.14-1.34) if the patient was hospitalized, 1.42 (95% CI: 1.27-1.57) and 1.45 (95% CI: 1.31-1.60) if the patient was ICU-admitted, and 1.34 (95% CI: 1.22-1.46) and 1.36 (95% CI: 1.22-1.51) if the patient died. Individuals with a significant person with hospitalized, ICU-admitted, or fatal COVID-19 showed elevated prevalence of depression and anxiety during the entire year after the COVID-19 diagnosis. Interpretation: Family members and close friends of critically ill COVID-19 patients show persistently elevated prevalence of depressive and anxiety symptoms. Funding: This study was primarily supported by NordForsk (COVIDMENT, 105668) and Horizon 2020 (CoMorMent, 847776).

Indexed as

AnxietyCOVID-19Cross-country studyDepressionSignificant person

Identifiers

PMID37953992
PMCPMC10636287
OpenAlexW4386408475

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.